FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The study compares the overall survival (OS) of FH‐006 and the second‐line chemotherapyselected by the investigators for treating esophageal squamous cell carcinoma patients.
Epistemonikos ID: f0b4e77d34e53851fc1d58f62ca1495f1de1b865
First added on: Aug 27, 2026